Zubair Khalid

Virologist/Molecular Biologist | Veterinarian | Bioinformatician

Conventional & Molecular Virology • Vaccine Development • Computational Biology

Dr. Zubair Khalid is a veterinarian and virologist specializing in conventional and molecular virology, vaccine development, and computational biology. Dedicated to advancing animal health through innovative research and multi-omics approaches.

Dr. Zubair Khalid - Veterinarian, Virologist, and Vaccine Development Researcher specializing in Computational Biology, Multi-omics, Animal Health, and Infectious Disease Research

Section: Infrastructure, Cloud & Policy

Multi-Omics Integration: A Practical Workflow for Combining Proteomics, Metabolomics, and Epigenomics Data

Multi-omics integration combines data from proteomics, metabolomics, epigenomics, and other molecular layers to identify biological patterns that single-omics analysis cannot reveal. This workflow guide covers data preprocessing, normalization, batch effect correction, and integration methods including MOFA and DIABLO, with practical decision criteria for researchers managing heterogeneous omics datasets.

Scope and Reader Context

This article serves students, researchers, analysts, and life-science professionals who need a practical workflow for combining proteomics, metabolomics, and epigenomics data. The focus is on concrete decisions: which preprocessing steps to apply, how to handle missing values, when to use unsupervised versus supervised integration, and how to select appropriate tools. The workflow assumes you have already generated raw omics data and need a structured path from quality control to biological interpretation.

Multi-omics studies generate vast amounts of biological data that can be integrated to examine the complex molecular underpinnings of health and disease, but integrative analysis is complicated by high dimensionality, data heterogeneity, and the lack of universal analysis protocols [8]. The growing number of multi-omics studies demands clear conceptual workflows coupled with easy-to-use software tools to facilitate data analysis and interpretation [6].

At a Glance: Multi-Omics Integration Workflow Overview

The table below summarizes the key stages of a multi-omics integration workflow, the primary decisions at each stage, and the tools or approaches commonly used.

Workflow Stage Primary Decisions Common Tools or Approaches
Data preprocessing Missing value handling, filtering, transformation Per-omics quality control, missing value imputation or removal [9]
Normalization Scaling method, within-omics versus across-omics scaling Variance stabilization, quantile normalization, z-score scaling [6]
Batch effect correction Batch detection, correction method, validation ComBat, limma removeBatchEffect, per-assay scaling [20]
Integration method selection Unsupervised versus supervised, data types, research question MOFA+, DIABLO, jSVD, deep learning models [16][17]
Interpretation and validation Biological relevance, external validation, reproducibility Pathway enrichment, network analysis, independent cohort validation [13]

Core Principles of Multi-Omics Integration

Why Integrate Multiple Omics Layers

Biological systems function through complex interactions between various biomolecules, and a more complete understanding of these systems is only possible through an integrated multi-omic perspective [9]. Individual subsystems do not act in isolation but instead interact with each other to drive health and disease, so individual subsystems are now analysed jointly to promote a holistic understanding of the underlying biological complexity [14].

For example, a deep learning-based model integrating RNA sequencing, miRNA sequencing, and methylation data from hepatocellular carcinoma patients identified survival subgroups that were validated across five external datasets, demonstrating that multi-omics integration can produce robust prognostic models [5]. Similarly, integrating transcriptomic and metabolomic data from the placenta-brain axis perspective enabled prediction models that correctly classified autism spectrum disorder symptoms in 99.7 percent of cases, attention-deficit/hyperactivity disorder symptoms in 99.0 percent, and intellectual disability symptoms in 95.7 percent [12].

The Challenge of Data Heterogeneity

Multi-omics data integration is not straightforward and is particularly complicated by the high dimensionality and heterogeneity of the data and by the lack of universal analysis protocols [8]. Each omics layer has distinct measurement scales, noise profiles, and missing data patterns. Proteomics data from mass spectrometry have different distributions than metabolomics data from chromatography or epigenomics data from sequencing.

A principal challenge to multi-omic integration is missing data because all biomolecules are not measured in all samples [9]. Missing data can arise from cost constraints, instrument sensitivity, or other experimental factors, and a biological sample may lack data for one or more omics technologies [9]. Many integration techniques assume access to completely observed data, so you must address missingness before applying most integration methods [9].

The Value of Complementary Methods

Using different multiscalar data integration strategies on the same data can enable identification and prioritization of disease mechanisms [13]. In a study of chronic kidney disease progression, two orthogonal integration approaches, one unsupervised and one supervised, both identified eight urinary proteins significantly associated with long-term outcomes and three shared enriched pathways [13]. This finding suggests that applying complementary methods can increase confidence in results.

However, integrating more omics data does not always produce better results. A comprehensive evaluation of ten integration methods for cancer subtyping showed that there are situations where integrating more omics data negatively impacts the performance of integration methods [17]. This finding refutes the widely held intuition that incorporating more types of omics data always produces better results [17].

Data Preprocessing and Quality Control

Per-Omics Quality Control

Before any integration step, each omics dataset must undergo individual quality control. The preprocessing of multi-omics datasets typically includes removing repeat features, scaling by assay, and removing outliers [20]. For proteomics data, this may involve filtering proteins with low detection rates across samples. For metabolomics data, this may involve removing features with high coefficients of variation in technical replicates. For epigenomics data, this may involve filtering probes or regions with low coverage.

The Analyst software suite protocol for multi-omics analysis begins with single-omics data analysis before any integration is attempted [6]. This stepwise approach allows you to identify problematic samples or features within each omics layer before combining data.

Missing Value Handling

Missing data is a principal challenge in multi-omic integration because all biomolecules are not measured in all samples [9]. You have several options for handling missing values:

  1. Remove features with high amounts of missing values. This approach was used in the FluPRINT vaccine response analysis, where features with high amounts of missing values were removed and the remaining missing values were ignored [20].
  2. Impute missing values using methods appropriate to each omics data type. Traditional missing data workflows have limitations, and recent methodological developments in artificial intelligence and statistical learning have facilitated the analysis of multi-omics data with missing values [9].
  3. Use integration methods that can handle partially observed samples. A subset of integration methods incorporate mechanisms for handling partially observed samples [9].

The choice of missing value strategy depends on the proportion of missing data, the mechanism of missingness, and the downstream integration method. Document your missing value decisions in the analysis protocol because they can substantially affect results.

Normalization and Scaling

Normalization is required to make different omics layers comparable. Each omics technology produces data on different scales, and integration methods typically require scaled data. The FluPRINT analysis scaled data by assay before applying integration methods [20].

Common normalization approaches include:

  • Variance stabilization for count-based data such as RNA sequencing or methylation counts
  • Quantile normalization for array-based data
  • Z-score scaling across features within each omics layer
  • Log transformation for mass spectrometry intensity data

The choice of normalization method should be guided by the data type and the assumptions of the integration method. Document the normalization approach for each omics layer and apply it consistently across all samples.

Batch Effect Correction

Batch effects can arise from sample processing dates, instrument calibration, reagent lots, or operator changes. These technical sources of variation can obscure biological signals and create false associations. Batch effect correction should be applied within each omics layer before integration.

The FluPRINT analysis included scaling by assay as part of preprocessing, which addresses some batch-related variation [20]. For datasets with known batch structure, methods such as ComBat or limma removeBatchEffect can be applied. After correction, verify that batch structure no longer explains significant variance in the data.

Integration Methods and Tool Selection

Unsupervised Integration Methods

Unsupervised integration methods identify patterns in multi-omics data without using outcome labels. These methods are suitable for disease subtyping, module discovery, and network analysis [16]. Multi-Omics Factor Analysis (MOFA+) is a widely used unsupervised method that identifies latent factors explaining variability across multiple omics layers.

MOFA+ has been applied to integrate transcriptomics, proteomics, metabolomics, cytokinome, and 16S microbiome profiles from prediabetic and healthy individuals, identifying ten latent factors with one factor emerging as most significant in distinguishing prediabetic samples from controls [19]. In breast cancer research, MOFA+ integrated transcriptomic, proteomic, and metabolomic data to reveal three prominent multi-omics clusters with significantly different long-term prognoses, and these clusters were validated in two independent large cohorts [24].

A comparative analysis of statistical and deep learning-based multi-omics integration for breast cancer subtype classification found that MOFA+ outperformed a deep learning approach in feature selection, achieving the highest F1 score in a nonlinear classification model and identifying more relevant pathways [22]. This finding suggests that MOFA+ is an effective unsupervised tool for feature selection in cancer subtyping [22].

Supervised Integration Methods

Supervised integration methods use outcome labels to identify features that distinguish groups. DIABLO (Data Integration Analysis for Biomarker discovery using Latent cOmponents) is a supervised method that identifies components that discriminate between predefined groups while maximizing correlation between omics layers.

A computational workflow combining transcriptomics, proteomics, and drug screening data from cell lines used a supervised approach called POPLS-DA to prioritize genes and proteins that best distinguish cases and controls [11]. This method provided a larger interpretable gene set than other single- and multi-omic approaches [11].

Deep Learning Approaches

Deep learning methods can capture complex, often non-linear interactions that define biological systems [9]. A deep learning-based model on hepatocellular carcinoma data integrated RNA sequencing, miRNA sequencing, and methylation data to predict prognosis, achieving a concordance index of 0.68 in the training cohort and validating across five external datasets with concordance indices ranging from 0.67 to 0.82 [5].

Machine learning and deep learning approaches have become central to biomarker discovery from proteomics data, with predictions from amino acid sequences alone improving the quality and reliability of analytical workflows [7]. However, model transparency and explainability are required to deploy biomarkers in clinical settings [7].

Knowledge-Driven Integration

Knowledge-driven integration uses biological networks and pathway information to guide the integration process. The Analyst software suite protocol includes knowledge-driven integration using biological networks through OmicsNet [6]. This approach can help interpret integration results in the context of known biological relationships.

Data-driven integration through joint dimensionality reduction is another approach, as implemented in OmicsAnalyst [6]. The choice between knowledge-driven and data-driven approaches depends on the availability of prior biological knowledge and the research question.

Tool Selection Decision Table

The following table provides decision criteria for selecting integration tools based on data types and research questions.

Research Question Data Types Recommended Approach Example Tools
Disease subtyping or patient stratification Multiple omics layers, no outcome labels Unsupervised factor analysis or clustering MOFA+, jSVD [16][24]
Biomarker discovery with known groups Multiple omics layers with case-control labels Supervised discriminant analysis DIABLO, POPLS-DA [11]
Survival prediction or prognosis Multiple omics layers with survival outcomes Deep learning or penalized regression Deep learning models [5]
Mechanistic pathway discovery Multiple omics layers with or without labels Knowledge-driven network integration OmicsNet, network analysis [6][13]

Practical Workflow for Multi-Omics Integration

Step 1: Define the Research Question and Data Requirements

Before beginning analysis, define the research question clearly. Are you seeking to identify disease subtypes, discover biomarkers, predict outcomes, or understand mechanisms? The research question determines whether you need unsupervised or supervised integration methods.

Consider whether your data types are appropriate for the question. A study of childhood type 1 diabetes using circulating immunome, transcriptome, and serum metabolic hormones found no associations between integration factors and clinical parameters, genetic predisposition, or disease outcome [23]. This negative result suggests that blood-derived omics data may not suffice to identify distinct subtypes of type 1 diabetes [23].

Step 2: Perform Per-Omics Quality Control and Preprocessing

Apply quality control and preprocessing steps to each omics dataset individually before integration. This includes:

  1. Filtering low-quality features and samples
  2. Handling missing values according to a documented strategy
  3. Normalizing data within each omics layer
  4. Correcting batch effects where applicable
  5. Scaling data appropriately for integration

The Analyst software suite protocol covers single-omics data analysis as the first component of multi-omics analysis [6]. This step ensures that each omics layer is clean before integration.

Step 3: Assess Data Completeness and Overlap

Determine which samples have data across all omics layers. Missing data is a principal challenge in multi-omic integration because all biomolecules are not measured in all samples [9]. Decide whether to restrict analysis to complete cases, impute missing values, or use integration methods that handle partial observations.

Step 4: Select and Apply Integration Method

Choose an integration method based on the research question, data types, and sample size. Use the decision table above as a starting point. Apply the method and document parameters.

For unsupervised integration with MOFA+, you will need to specify the number of factors to extract. The choice of factor number can be guided by the variance explained and biological interpretability of factors. In the type 2 diabetes study, MOFA+ identified ten latent factors, with one factor emerging as most significant in distinguishing prediabetic samples from controls [19].

Step 5: Validate Results

Validation is essential for multi-omics integration results. Approaches include:

  1. External validation in independent cohorts. The deep learning model for hepatocellular carcinoma was validated on five external datasets of various omics types [5].
  2. Cross-validation within the dataset. The breast cancer multi-omics clusters were validated in two independent large cohorts, METABRIC and TCGA [24].
  3. Biological validation through pathway enrichment and literature review. The chronic kidney disease study identified three shared enriched pathways across two integration methods [13].

Step 6: Interpret and Report Results

Interpret integration results in the context of biological knowledge. Use pathway enrichment analysis to identify biological processes represented by key features. Report the analysis steps, parameters, and validation results to enable reproducibility.

Records and Measurements for Multi-Omics Analysis

Documentation Requirements

Maintain detailed records of all analysis steps to ensure reproducibility. Documentation should include:

  1. Raw data file locations and versions
  2. Preprocessing steps applied to each omics layer
  3. Missing value handling decisions
  4. Normalization and scaling methods
  5. Batch effect correction approach
  6. Integration method and parameters
  7. Validation approach and results
  8. Software versions and computational environment

The FAIR Guiding Principles provide a framework for making data findable, accessible, interoperable, and reusable [4]. Applying these principles to multi-omics data and analysis workflows supports reproducibility and data sharing.

Quality Metrics to Track

Track quality metrics at each stage of the workflow:

  1. Number of features before and after filtering
  2. Proportion of missing values before and after imputation
  3. Variance explained by batch effects before and after correction
  4. Variance explained by each integration factor
  5. Model performance metrics such as concordance index, F1 score, or area under the receiver operating characteristic curve
  6. Stability of results across cross-validation folds

The FluPRINT analysis reported area under the receiver operating characteristic curve values for MOFA and Stabl features, providing quantitative comparison of method performance [20].

Common Failure Patterns in Multi-Omics Integration

Overintegration and Performance Degradation

Integrating more omics data does not always produce better results. A comprehensive evaluation showed that there are situations where integrating more omics data negatively impacts the performance of integration methods [17]. This failure pattern occurs when additional omics layers add noise instead of signal, or when sample overlap across omics layers is limited.

To avoid this failure, evaluate whether each additional omics layer improves or degrades integration performance. Consider running integration with different combinations of omics layers and comparing results.

Data Fusion Does Not Always Improve Classification

A study evaluating data fusion approaches for cutaneous melanoma subtyping found that data fusion did not generate classification results superior to those obtained using single-domain data [15]. The authors noted that data from different domains are not entirely independent from each other, and molecular classes are characterized by features that penetrate different domains [15].

This finding suggests that data fusion techniques might be better suited for response prediction, where they could contribute to the identification of predictive features in a domain-independent manner [15].

Missing Data Mismanagement

Missing data is a principal challenge to multi-omic integration [9]. Common failure patterns include:

  1. Removing all samples with any missing data, which can drastically reduce sample size
  2. Imputing missing values without considering the missing data mechanism
  3. Using integration methods that assume complete data when substantial missingness exists

Recent methodological developments in artificial intelligence and statistical learning have facilitated the analysis of multi-omics data with missing values, but many techniques assume access to completely observed data [9].

Lack of Biological Validation

Integration results that are statistically significant but biologically meaningless represent a common failure pattern. The type 1 diabetes study found no associations between integration factors and clinical parameters, genetic predisposition, or disease outcome, challenging the assumption that blood-derived omics data can identify disease subtypes [23].

To avoid this failure, validate integration results through pathway enrichment analysis, literature review, and external cohort validation where possible.

Limitations and Interpretation Boundaries

Statistical Limitations

Multi-omics integration methods have several statistical limitations:

  1. High dimensionality relative to sample size increases the risk of overfitting
  2. Multiple testing across many features requires appropriate correction
  3. Correlation does not imply causation, and integration methods identify associations, not mechanisms
  4. Batch effects can create spurious associations if not properly corrected

The lack of gold standards for evaluating integration methods complicates method comparison [17]. Questions of practical importance remain regarding the impact of selecting appropriate data types and combinations on the performance of integrative studies [17].

Biological Interpretation Limits

Integration results must be interpreted within the context of the measured omics layers. The type 1 diabetes study found that a combination of clinical phenotypes might be responsible for the differences across cases, suggesting that blood-derived omics data may not suffice to identify distinct subtypes [23].

The hepatocellular carcinoma deep learning model identified more aggressive subtypes associated with TP53 inactivation mutations, higher expression of stemness markers, and activated Wnt and Akt signaling pathways [5]. These findings provide biological context for the integration results but require experimental validation.

Clinical Translation Challenges

Clinical translation of multi-omics research remains challenging [14]. Model transparency and explainability are required to deploy biomarkers in clinical settings [7]. Data privacy considerations are also important when working with human data.

The NIH Genomic Data Sharing Policy provides requirements for sharing genomic data generated with NIH funding [3]. Researchers should be aware of applicable data sharing policies and ensure compliance.

Safety and Regulatory Context

Data Privacy and Sharing

Multi-omics data often include human subject data with privacy considerations. The NIH Genomic Data Sharing Policy outlines expectations for responsible sharing of genomic data [3]. Researchers should ensure that data sharing plans comply with applicable regulations and institutional requirements.

The FAIR Guiding Principles provide a framework for making data findable, accessible, interoperable, and reusable [4]. Applying these principles supports responsible data sharing while maintaining appropriate access controls.

Reproducibility Requirements

Reproducibility is essential for multi-omics integration research. Document all analysis steps, software versions, and parameters. Consider sharing analysis code and processed data to enable others to reproduce results.

The Analyst software suite protocol enables researchers to perform a wide range of omics data analysis tasks via a user-friendly web interface, which can support reproducibility through standardized workflows [6].

Professional Escalation Criteria

When to Seek Expert Assistance

Consider consulting a bioinformatics specialist or statistician when:

  1. You encounter substantial missing data across multiple omics layers and are uncertain about appropriate handling methods
  2. Integration results are unstable across different parameter settings or cross-validation folds
  3. Batch effects remain significant after correction attempts
  4. You need to integrate more than three omics layers with complex dependencies
  5. Results from different integration methods conflict substantially
  6. You plan to use integration results for clinical decision-making or regulatory submissions

When to Reconsider the Study Design

Some situations warrant revisiting the study design instead of continuing analysis:

  1. Sample overlap across omics layers is too limited for meaningful integration
  2. The research question cannot be addressed with the available data types
  3. Integration results consistently fail validation in independent cohorts
  4. The biological interpretation of integration results is not supported by existing knowledge

The type 1 diabetes study provides an example where integration results did not support the hypothesized subtypes, leading the authors to conclude that a combination of clinical phenotypes might be responsible for the differences across cases [23].

Frequently Asked Questions

What is the difference between unsupervised and supervised multi-omics integration?

Unsupervised integration methods identify patterns in multi-omics data without using outcome labels. These methods are suitable for disease subtyping, module discovery, and network analysis [16]. Supervised integration methods use outcome labels to identify features that distinguish predefined groups. The choice depends on whether you have known group labels and whether your goal is discovery or prediction.

How do I handle missing data in multi-omics integration?

Missing data is a principal challenge in multi-omic integration because all biomolecules are not measured in all samples [9]. Options include removing features with high amounts of missing values, imputing missing values using methods appropriate to each omics data type, or using integration methods that can handle partially observed samples [9]. Document your missing value strategy because it can substantially affect results.

When should I use MOFA+ versus DIABLO?

MOFA+ is an unsupervised method suitable for disease subtyping and pattern discovery without outcome labels. DIABLO is a supervised method for biomarker discovery when you have predefined groups. A comparative analysis found that MOFA+ was a more effective unsupervised tool for feature selection in breast cancer subtyping [22]. Consider your research question and whether outcome labels are available.

Does integrating more omics data always improve results?

No. A comprehensive evaluation showed that there are situations where integrating more omics data negatively impacts the performance of integration methods [17]. Evaluate whether each additional omics layer improves or degrades integration performance by comparing results with different combinations of omics layers.

What validation approaches are recommended for multi-omics integration results?

External validation in independent cohorts is a strong approach. The deep learning model for hepatocellular carcinoma was validated on five external datasets [5]. Cross-validation within the dataset and biological validation through pathway enrichment are also useful. The chronic kidney disease study identified shared enriched pathways across two integration methods, increasing confidence in results [13].

Can multi-omics integration identify disease subtypes?

Multi-omics integration can identify disease subtypes in some contexts. The breast cancer study identified three prominent multi-omics clusters with significantly different long-term prognoses that were validated in independent cohorts [24]. However, the type 1 diabetes study found no associations between integration factors and clinical parameters, suggesting that blood-derived omics data may not suffice to identify distinct subtypes [23].

What are the main limitations of deep learning approaches for multi-omics integration?

Deep learning methods can capture complex, often non-linear interactions [9], but they require large sample sizes and careful validation. Model transparency and explainability are required to deploy biomarkers in clinical settings [7]. Deep learning approaches may also be more sensitive to missing data and require complete datasets or specialized handling.

How should I document my multi-omics integration workflow?

Maintain detailed records of raw data locations, preprocessing steps, missing value handling, normalization methods, batch effect correction, integration method parameters, validation results, and software versions. The FAIR Guiding Principles provide a framework for making data findable, accessible, interoperable, and reusable [4]. This documentation supports reproducibility and enables others to evaluate your results.

Related Bioinformatics Guides

References and Further Reading

This article is educational and does not replace validated analysis plans, institutional policy, clinical interpretation, or specialist review.